# Doug Quinn

> Doug Quinn is a seed investor at DSW Ventures (Manchester) backing Biotechnology and Therapeutics. See 8 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [DSW Ventures](https://shizune.co/investors/profile/dow-schofield-watts-angels)
- Location: Manchester, United Kingdom
- Total investments: 8
- Last investment: Mar 2026
- Lead investor: 63%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/doug-quinn-37103915
- Website: https://dsw.vc/team/doug-quinn

Doug Quinn is a partner at DSW Ventures.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 63% |
| Therapeutics | 2 | 25% |
| Fitness | 1 | 13% |
| Diabetes | 1 | 13% |
| Hospital | 1 | 13% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 5 | 63% |
| Series A | 2 | 25% |
| Pre-Seed | 1 | 13% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United Kingdom | 4 | 50% |
| United States | 2 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| RoxFit | RoxFit is the best HYROX workout tracker for preparation and performance on race day. | $2.5M | Seed | Mar 04, 2026 |  |
| InvenireX | InvenireX is a biotechnology company that offers molecular diagnostics services. | $2.6M | Seed | Nov 18, 2025 |  |
| RoxFit | RoxFit is the best HYROX workout tracker for preparation and performance on race day. | $1.1M | Pre-Seed | May 28, 2025 |  |
| Dia Beta Labs | DRG labs at Ulster, maintain full access to the cutting-edge facilities on-site and its connection to a group of scholars and experts in diseases. Afterward, lead molecules for animal research are identified by advancing therapeutic candidates through our discovery platform, which uses industry-standard methodologies and models. | $1.5M | Seed | Dec 09, 2024 |  |
| 4D Biomaterials | 4D Biomaterials develops novel solutions for the targeted and controlled regeneration of human tissue. |  | Series A | Jul 25, 2024 |  |
| 4D Medicine | 4D Medicine focuses on providing biomaterials and medical device solutions, particularly in the area of bioresorbable polymers. The company specializes in developing materials for 3D printing for medical applications, such as implants and devices that naturally dissolve in the body. It collaborates with partners to enhance innovation in the designand manufacturing processes for medical devices. Additionally, it offers design services to support commercial partners in advancing product development. | $4.4M | Series A | Jul 25, 2024 |  |
| Glen Clova Scientific | Glen Clova Scientific is a company that developing a new gneration of active biological drugs. | $5M | Seed | Apr 24, 2024 |  |
| Mesenbio | Mesenbio is a preclinical biopharmaceutical business based at the University of York. Its Cell Line Extracellular Vesicle Release (CLEVR) technique allows for a more diverse treatment pipeline by overcoming the most common hurdle in extracellular vesicle therapy. | $1.8M | Seed | Jan 09, 2024 |  |

8 of 8 investments shown.

## Co-investors
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund, 2 deals together
- [York Angels](https://shizune.co/investors/profile/york-angels) — VC Fund, 2 deals together
- [Boundary Capital Partners LLP](https://shizune.co/investors/profile/boundary-capital) — VC Fund, 1 deal together
- [Cambridge Technology Capital](https://shizune.co/investors/profile/cambridge-technology-capital) — VC Fund, 1 deal together
- [NG Bio](https://shizune.co/investors/profile/ng-bio) — VC Fund, 1 deal together
- [Norcliffe Capital](https://shizune.co/investors/profile/norcliffe-capital) — VC Fund, 1 deal together

## About DSW Ventures

VC Fund · Manchester, United Kingdom

DSW Ventures made its first investment in 2018 and is an investor in early-stage scale-up businesses requiring venture funding of more than £250,000, primarily on an EIS basis. It is funded by a growing network of high-net-worth angel investors. DSW Ventures is the trading style of DSW Angels LLP, which is part of the Dow Schofield Watts Group. DSWVentures is a partner in British Business Investments’ £100m Regional Angels Programme, designed to help reduce regional imbalances in access to early stage equity finance for smaller businesses across the UK.

4 contacts available at DSW Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Keith Benson | Partner | https://shizune.co/investors/profile/keith-benson-e2e0 |
| David Smith | Founding Partner | https://shizune.co/investors/profile/david-smith-10 |
| Doug Quinn | Partner | https://shizune.co/investors/profile/doug-quinn-59bf |
| James Reston | Investment Manager | https://shizune.co/investors/profile/james-reston-6d4b |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Doug Quinn invest in?

Doug Quinn invests primarily in Biotechnology, Therapeutics and Fitness startups, most often at Seed and Series A stage. Most of the 8 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Doug Quinn last invest?

The most recent investment recorded for Doug Quinn closed in Mar 2026. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co